Rationale for the Coadministration of Albendazole and Ivermectin to Humans for Malaria Parasite Transmission Control

Abstract

Recently there have been calls for the eradication of malaria and the elimination of soil-transmitted helminths (STHs). Malaria and STHs overlap in distribution, and STH infections are associated with increased risk for malaria. Indeed, there is evidence that suggests that STH infection may facilitate malaria transmission. Malaria and STH coinfection may exacerbate anemia, especially in pregnant women, leading to worsened child development and more adverse pregnancy outcomes than these diseases would cause on their own. Ivermectin mass drug administration (MDA) to humans for malaria parasite transmission suppression is being investigated as a potential malaria elimination tool. Adding albendazole to ivermectin MDAs would maximize effects against STHs. A proactive, integrated control platform that targets malaria and STHs would be extremely cost-effective and simultaneously reduce human suffering caused by multiple diseases. This paper outlines the benefits of adding albendazole to ivermectin MDAs for malaria parasite transmission suppression.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 28, 2014
Accession Number
ADA611441

Entities

People

  • Archie Clements
  • Brett E. Swierczewski
  • Brian D. Foy
  • Haoues Alout
  • Jason H. Richardson
  • Kevin C Kobylinski
  • Poom Adisakwattana

Organizations

  • Walter Reed Army Institute of Research

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biology
  • Cells
  • Coinfection
  • Diseases And Disorders
  • Electronic Mail
  • Elimination
  • Helminthiasis
  • Infection
  • Infectious Diseases
  • Malaria
  • Nematoda
  • Parasites
  • Pest Control
  • Platforms
  • Risk Factors
  • Therapy
  • Wound Infections

Fields of Study

  • Medicine

Readers

  • Parasitology and Pharmacology of Malaria.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.